Full-Time

Assistant Controller/Accounting Director

Posted on 8/20/2024

Alamar Biosciences

Alamar Biosciences

51-200 employees

Develops technology for protein detection and measurement

Compensation Overview

$180k - $200k/yr

+ Bonus + Equity + Benefits

Senior, Expert

Fremont, CA, USA

Category
Cost Accounting
Financial Accounting
Management Accounting
Accounting
Required Skills
NetSuite
Requirements
  • Bachelor's degree in Accounting, Finance, or related field
  • 7+ years of experience in a finance or accounting role with substantial management and operational exposure
  • Strong knowledge of GAAP and financial reporting standards
  • Proficiency in Microsoft Office and Netsuite
  • Excellent analytical and problem-solving skills
  • Strong communication and interpersonal skills
  • Ability to work independently and as part of a team
  • Has the ability to handle multiple high priority projects with accuracy
Responsibilities
  • Oversee the financial close process, ensuring accurate recording of transactions (including journal entries, accruals, reconciliations and consolidation)
  • Assist with the preparation of monthly, quarterly, and annual consolidated financial statements
  • Manage inventory and related cost accounting
  • Prepare and analyze complex financial and operational data and provide accurate and timely financial recommendations for decision-making purposes and strategic initiatives
  • Stays current with all applicable accounting, tax and other regulations and requirements, adapting policies and practices accordingly
  • Assist with the implementation and maintenance of internal controls
  • Support the Controller with audit preparations, technical memo drafting, and compliance
  • Manage accounting team members
  • Other duties as assigned

Alamar Biosciences focuses on the study of proteins, known as proteomics, to enhance disease detection and treatment. The company has created NULISA™, a technology that can detect and measure proteins in the human body with high sensitivity. This allows researchers and clinicians to profile clinically relevant protein biomarkers, which are essential for developing new diagnostic tests and treatments. Alamar's ARGO™ system complements NULISA™ by providing a fully automated platform for high-throughput precision proteomics, enabling users to analyze multiple protein targets in a single experiment. Unlike competitors, Alamar's technology simplifies the process, reducing the need for extensive technical expertise, making it accessible to a broader range of clients. The goal of Alamar Biosciences is to improve our understanding of proteins in health and disease, ultimately leading to better early detection and treatment options for various diseases.

Company Size

51-200

Company Stage

Grant

Total Funding

$232M

Headquarters

Hayward, California

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • AI integration enhances NULISA™ technology for precise and faster protein data analysis.
  • Personalized medicine trends increase demand for Alamar's early disease detection technologies.
  • New distribution partners expand Alamar's global presence, especially in Asia-Pacific.

What critics are saying

  • Emerging competition from Olink Proteomics and SomaLogic may impact Alamar's market share.
  • Rapid technological advancements require continuous innovation, straining Alamar's resources.
  • Economic instability in Asia-Pacific could affect new distribution partnerships and revenue.

What makes Alamar Biosciences unique

  • Alamar's NULISA™ technology offers unprecedented sensitivity in protein detection.
  • The ARGO™ system provides a fully automated, high-throughput precision proteomics platform.
  • Alamar's technology reduces the need for technical expertise, broadening its client base.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

401(k) Retirement Plan

Performance Bonus

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

9%
PR Newswire
Mar 24th, 2025
Alamar Biosciences Announces The Launch Of The Nulisaseq Mouse Panel 120

Providing the largest and most comprehensive, high sensitivity, protein biomarker analysis to advance pre-clinical researchFREMONT, Calif., March 24, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the launch of the NULISAseq Mouse Panel 120, an innovative biomarker profiling solution that provides the most comprehensive coverage of protein targets for expression analysis in mouse models. Designed to facilitate biomedical research and pre-clinical development studies, this cutting-edge panel analyzes 120 proteins covering key pathways in inflammation, neurodegeneration and immuno-oncology."The NULISAseq Mouse Panel 120 encompasses an unparalleled selection of proteins essential for studying key biological pathways in pre-clinical models," said Yuling Luo, Ph.D., Founder, Chairman and CEO of Alamar Biosciences. "This robust panel is designed specifically for mouse models enabling researchers to gain valuable insights into disease mechanisms and therapeutic efficacy."With the broadest coverage of mouse protein targets, the NULISAseq Mouse Panel 120 is the only multiplex panel to include a specific focus on neurology content. This is crucial for researchers studying neurodegenerative diseases and the neurological effects of potential treatments."I'm excited to incorporate the NULISAseq Mouse Panel 120 panel into my research studies." said Cheryl Wellington, Ph.D., Professor, Department of Pathology and Laboratory Medicine at University of British Columbia. "This state-of-the art panel provides me with the broadest view of neuro-physiology and has the potential to uncover new insights into the mechanisms of dementia and traumatic brain injury."Built on Alamar's novel multiplexing technology, the NULISAseq Mouse Panel 120 offers researchers a high-sensitivity, high-throughput solution to uncover complex biological mechanisms. The panel's attomolar (fg/ml) sensitivity and 10 logs of dynamic range allows for the detection of a wide range of proteins found in mouse plasma, even those that are low in abundance, such as p-tau217, from as little as 5 µl sample input.For more information, please visit alamarbio.com.About Alamar Biosciences, Inc.Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease

PR Newswire
Mar 19th, 2025
Alamar Biosciences Announces First Five Distribution Partners, Expanding Commercial Support In Asia Pacific

FREMONT, Calif., March 19, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce the signing of five new distribution partners to expand its global presence. The company has partnered with established industry leaders across key international markets to enhance access to its innovative proteomics technologies.The newly signed distribution partners include:GeneWorks – Australia and New Zealand– and Genomax – Singapore– PhileKorea – South Korea– Scrum Inc. – Japan– Spinco – India"We are excited to welcome these outstanding partners to the Alamar network," said Yuling Luo, Ph.D., Founder, Chairman and CEO of Alamar Biosciences, "Their deep expertise in the life sciences industry and strong regional presence will allow us to bring our next-generation proteomics solutions to more researchers and clinicians worldwide."Alamar's technology empowers scientists to achieve groundbreaking insights in biomarker discovery, drug development, and disease research. Through these new partnerships, researchers in Asia-Pacific will now have enhanced access to Alamar's cutting-edge platforms and technical support.Alamar remains committed to supporting the scientific community with best-in-class tools that enable high-sensitivity protein analysis. For more information on Alamar's distribution network and solutions, visit alamarbio.com.About Alamar Biosciences, Inc.Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today

PR Newswire
Feb 25th, 2025
Alamar Biosciences Начинает Выпуск Набора Для Разработки Индивидуальных Анализов Nulisaqpcr™, Чтобы Ускорить Разработку Новых Биомаркерных Анализов Для Клинических Исследований

ФРИМОНТ, Калифорния, 25 февраля 2025 г. /PRNewswire/ -- Компания Alamar Biosciences, создающая возможности для использования высокоточной протеомики с целью раннего выявления заболеваний, с гордостью объявляет о начале выпуска набора для разработки индивидуальных анализов NULISAqpcr™, новаторского продукта, который позволит исследователям создавать высокочувствительные и точные анализы биомаркеров, адаптированные к их конкретным исследовательским потребностям, и расширит применение технологии NULISA™ для широкого сообщества исследователей биомаркеров

PR Newswire
Feb 25th, 2025
Alamar Biosciences Bringt Nulisaqpcr™ Custom Assay Development Kit Auf Den Markt, Um Die Entwicklung Neuer Biomarker-Assays Für Die Klinische Forschung Voranzutreiben

FREMONT, Kalifornien, 25. Februar 2025 /PRNewswire/ -- Alamar Biosciences, ein Unternehmen, das Präzisionsproteomik zur frühestmöglichen Erkennung von Krankheiten vorantreibt, freut sich, die Markteinführung des NULISAqpcr™ Custom Assay Development Kitankündigen zu können. Dabei handelt es sich ein bahnbrechendes Produkt, das es Forschenden ermöglicht, hochempfindliche und präzise Biomarker-Assays zu erstellen, die auf ihre spezifischen Forschungsbedürfnisse zugeschnitten sind, und die Anwendung der NULISA™-Technologie auf die breitere Biomarker-Forschungsgemeinschaft auszuweiten

PR Newswire
Feb 25th, 2025
Alamar Biosciences Wprowadza Do Sprzedaży Nulisaqpcr™ Custom Assay Development Kit - Zestaw Narzędzi, Który Ułatwi Opracowywanie Nowatorskich Testów Biomarkerowych Na Potrzeby Badań Klinicznych

FREMONT, Kalifornia, 25 lutego 2025 r. /PRNewswire/ -- Alamar Biosciences, firma tworząca rozwiązania wykorzystywane w proteomice precyzyjnej w celu jak najwcześniejszego wykrywania chorób, z dumą ogłasza premierę NULISAqpcr™ Custom Assay Development Kit - przełomowego produktu umożliwiającego naukowcom tworzenie wysoce czułych i ukierunkowanych testów biomarkerowych, które odpowiadają na specyficzne potrzeby prowadzonych przez nich badań. Tym samym technologia NULISA™ znajdzie szersze zastosowanie w obszarze badań nad biomarkerami

INACTIVE